Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Multimodal Digital Biomarker Prediction of Acute Clinical Deterioration (FUSION-72)

9 września 2026 zaktualizowane przez: Truway Health, Inc.

Multimodal Physiologic Signal Fusion for 72-Hour Prediction of Acute Clinical Deterioration

Rather than relying on a single abnormal vital sign, the study will examine how multiple physiologic signals change together over time and whether changes in the relationships among these signals provide useful information about impending clinical deterioration. Individual participant physiologic patterns may be characterized longitudinally to account for differences between individuals and changes within the same individual over time.

The primary objective is to evaluate the predictive accuracy of multimodal digital biomarkers for protocol-defined acute clinical deterioration occurring within 72 hours. The study is observational and does not assign participants to an investigational treatment.

Przegląd badań

Status

Rejestracja na zaproszenie

Warunki

Interwencja / Leczenie

Szczegółowy opis

FUSION-72 (Multimodal Physiologic Signal Fusion for 72-Hour Prediction of Acute Clinical Deterioration) is a prospective, longitudinal, observational study designed to investigate multimodal digital biomarkers associated with acute clinical deterioration. The central scientific premise is that clinically meaningful deterioration may be preceded not only by an abnormal value in an individual physiologic parameter, but also by coordinated or discordant changes occurring across multiple physiologic, behavioral, and symptom domains.

The study will collect longitudinal data from multiple digital and physiologic sources, which may include wearable electrocardiography (ECG), photoplethysmography (PPG), peripheral oxygen saturation (SpO2), temperature, gait and activity characteristics, sleep measures, voice characteristics, cough characteristics, and participant-reported symptoms.

These multimodal measurements will be temporally aligned and analyzed to characterize changes within individual participants and relationships among physiologic, behavioral, acoustic, and symptom-derived signals. Analyses will evaluate whether multimodal signal fusion provides additional predictive information beyond individual digital biomarker streams or conventional single-parameter measurements.

The primary objective is to evaluate the predictive accuracy of a prespecified multimodal digital biomarker model for protocol-defined acute clinical deterioration occurring within a subsequent 72-hour prediction window. Secondary objectives include evaluation of time-dependent predictive performance, lead time to detection, incremental predictive value of multimodal signal relationships, model calibration, and robustness of predictive performance across prespecified participant and clinical subgroups.

The study is observational. No investigational treatment is assigned, and participation does not direct, replace, or require modification of usual clinical care or medical management.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

10000

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Stany Zjednoczone
    • New York
      • New York, New York, Stany Zjednoczone, 10016
        • Truway Health, Inc.

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

FUSION-72 will enroll an adult longitudinal cohort for prospective evaluation of multimodal digital biomarkers associated with acute clinical deterioration. Participants will undergo protocol-specified collection of wearable and remote digital measurements, including ECG, PPG, oxygen saturation, temperature, gait, sleep, voice, cough, and participant-reported symptoms. The study is designed to evaluate temporal and cross-signal relationships and their ability to predict protocol-defined clinical deterioration within 72 hours.

Opis

Inclusion Criteria:

  • Adults aged 18 through 90 years at enrollment.
  • Able to provide informed consent, or have a legally authorized representative provide consent when permitted by the applicable protocol and regulations.
  • Able and willing to participate in prospective longitudinal digital biomarker monitoring.
  • Able to use, or permit application of, study-authorized wearable or remote-monitoring technologies.
  • Able and willing to provide protocol-specified physiologic, behavioral, acoustic, and symptom data.
  • Expected to have sufficient follow-up to permit evaluation of the 72-hour prediction endpoint.
  • Willing to comply with study procedures and data-collection requirements.

Exclusion Criteria:

  • Inability to provide informed consent or otherwise participate through an approved consent process.
  • Clinical or technical circumstances that prevent reliable collection of the required multimodal digital biomarker data.
  • Inability or unwillingness to comply with study monitoring procedures.
  • Enrollment in another study that, in the investigator's judgment, would materially interfere with FUSION-72 data collection or endpoint assessment.
  • Any circumstance that, in the investigator's judgment, would make participation inappropriate or compromise the integrity of the study.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
FUSION-72 Prospective Multimodal Monitoring Cohort
Participants enrolled in a prospective longitudinal observational cohort undergoing multimodal digital biomarker monitoring. Participants will contribute wearable and digital measurements including electrocardiography (ECG), photoplethysmography (PPG), oxygen saturation, temperature, gait, sleep, voice, cough, and participant-reported symptoms. Data will be analyzed longitudinally to characterize temporal changes and relationships among physiologic and behavioral signals and to evaluate prediction of protocol-defined acute clinical deterioration within 72 hours. No investigational treatment or therapeutic intervention is assigned by the study.
Inny: Multimodal Digital Biomarker Monitoring
Prospective collection and analysis of multimodal digital biomarkers derived from wearable and remote-monitoring technologies, including ECG, PPG, oxygen saturation, temperature, gait, sleep, voice, cough, and participant-reported symptom data. The monitoring is observational and does not direct or replace clinical care, does not assign treatment, and does not require modification of participants' usual medical management. Multimodal signals will be temporally aligned and evaluated for changes in inter-signal relationships associated with protocol-defined clinical deterioration occurring within the subsequent 72-hour prediction window.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Predictive Accuracy of Multimodal Digital Biomarker Fusion for Acute Clinical Deterioration Within 72 Hours
Ramy czasowe: At initiation of each prespecified prediction episode and 72 hours after initiation of each prespecified prediction episode.
Performance of the prespecified multimodal digital biomarker model in predicting protocol-defined acute clinical deterioration during the subsequent 72-hour prediction window. Model performance will be evaluated using the area under the receiver operating characteristic curve (AUROC), with additional assessment of the area under the precision-recall curve (AUPRC), sensitivity, specificity, positive predictive value, negative predictive value, and calibration.
At initiation of each prespecified prediction episode and 72 hours after initiation of each prespecified prediction episode.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Time-Dependent Predictive Performance of Individual and Combined Digital Biomarkers
Ramy czasowe: At initiation of each prespecified prediction episode and 72 hours after initiation of each prespecified prediction episode.
Comparison of predictive performance associated with individual and multimodal combinations of electrocardiography (ECG), photoplethysmography (PPG), peripheral oxygen saturation (SpO2), temperature, gait, sleep, voice, cough, and symptom-derived features for prediction of protocol-defined acute clinical deterioration.
At initiation of each prespecified prediction episode and 72 hours after initiation of each prespecified prediction episode.
Lead Time to Detection of Acute Clinical Deterioration
Ramy czasowe: For each protocol-defined acute clinical deterioration event, during the 72 hours preceding event occurrence and ending at the time of event occurrence.
Time interval, measured in hours, between the earliest prespecified model-generated deterioration signal meeting protocol-defined prediction criteria and occurrence of the corresponding protocol-defined acute clinical deterioration event.
For each protocol-defined acute clinical deterioration event, during the 72 hours preceding event occurrence and ending at the time of event occurrence.
Incremental Predictive Value of Multimodal Signal Relationships
Ramy czasowe: At initiation of each prespecified prediction episode and 72 hours after initiation of each prespecified prediction episode.
Assessment of whether incorporating prespecified temporal relationships and interactions among multiple physiologic, behavioral, acoustic, and symptom-derived signals improves prediction of protocol-defined acute clinical deterioration compared with models based on individual signal domains or conventional single-parameter measurements.
At initiation of each prespecified prediction episode and 72 hours after initiation of each prespecified prediction episode.
Model Calibration for 72-Hour Clinical Deterioration Risk
Ramy czasowe: At 72 hours after initiation of each prespecified prediction episode.
Agreement between predicted probabilities of protocol-defined acute clinical deterioration and observed event frequencies within the subsequent 72-hour prediction horizon, assessed using prespecified calibration metrics.
At 72 hours after initiation of each prespecified prediction episode.
Robustness of Multimodal Prediction Across Participant and Clinical Subgroups
Ramy czasowe: At 72 hours after initiation of each prespecified prediction episode.
Evaluation of predictive performance across prespecified participant and clinical subgroups, including age category, sex, baseline health status, comorbidity burden, care setting, and availability or completeness of individual digital biomarker streams.
At 72 hours after initiation of each prespecified prediction episode.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Truway Health, Inc.

Śledczy

  • Główny śledczy: Gavin C Solomon, MD, Truway Health, Inc.

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Przydatne linki

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

1 września 2026

Zakończenie podstawowe (Szacowany)

30 września 2038

Ukończenie studiów (Szacowany)

31 marca 2039

Daty rejestracji na studia

Pierwszy przesłany

1 września 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 września 2026

Pierwszy wysłany (Rzeczywisty)

14 września 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

14 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

9 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • TH-FUSION72-2026-001

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

Individual participant data will not be shared with other researchers. Individual-level clinical, imaging, and other participant data will remain under the control of the participating research sites and will not be transferred to external investigators or deposited in a publicly accessible repository. The study may use privacy-preserving federated analysis in which participating sites retain source data locally and transmit only approved, non-identifying computational outputs, such as model parameters, aggregate statistics, or other de-identified results, as permitted by the protocol and applicable IRB requirements. Any sharing of aggregate or de-identified study findings will be conducted in accordance with the approved protocol, participant consent/authorization, applicable law, and institutional data-use policies.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj